Association of Adiponectin and Oxidized HDL with ABO Blood Groups in Fatty Liver Patients: Adiponectin and Oxidized High Density Lipoprotein in Fatty Liver

Naveeda Nawaz; Saba Arif; Rehan Anwar; Adnan Riaz; Asima Ayyub; Rafia Javed

doi:10.54393/pjhs.v5i07.1847

Authors

Naveeda Nawaz Department of Biochemistry, Mohi-Ud-Din Islamic Medical College, Mirpur, Pakistan
Saba Arif Department of Biochemistry, Akhtar Saeed Medical and Dental College, Lahore, Pakistan
Rehan Anwar Department of Medicine, Sialkot Medical College, Sialkot, Pakistan
Adnan Riaz Department of Biochemistry, Islam Medical College, Sialkot, Pakistan
Asima Ayyub Department of Biochemistry, Akhtar Saeed Medical and Dental College, Lahore, Pakistan
Rafia Javed Department of Biochemistry, Allama Iqbal Medical College, Lahore, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i07.1847

Keywords:

Fatty Liver, Adiponectin, Lipid Profile, Oxidized High Density Lipoprotein

Abstract

Non-Alcoholic Fatty Liver Disease (NAFLD) is a group of liver diseases that are not brought on by alcohol usage and are defined by an excessive buildup of fat in the liver cells. Objective: To identify the relationship between the Body Mass Index (BMI) and liver function markers in the study group, as well as Oxidized High-Density Lipoprotein (oxHDL) levels. Methods: This study was conducted at the University of Lahore, for the duration of six months from January 2022 to June 2022. For determining the role of adiponectin and oxHDL, (n=200) patients and divided into two group, healthy group (n=100) and disease group (n=100) participants. Biochemical identification, liver function test, lipid profile test and ELISA was done for analyzing the association with NAFLD. SPSS software was used for statistical analysis. Results: In this study different parameters were used that’s values of parameters mean of cases according to blood group system were varied than normal range, such as adiponectin level, BMI, oxLDL, oxHDL, ALT, AST, ALP, Cholesterol level, d-LDL, Calculated LDL, sdLDL, V-LDL, Triglyceride level, Apolipoprotein-B level was significantly higher and AST/ALT Ratio values, albumin, HDL were slightly less than normal values. O Blood groups was reported very low risk of fatty liver patients due to high adiponectin. Conclusions: From analysis it was concluded, that adiponectin and oxHDL associated with high risk of non-alcoholic fatty liver disorder.

References

Kelly N and Wattacheril J. Nonalcoholic fatty liver disease: Evidence-based management and early recognition of nonalcoholic steatohepatitis. The Journal for Nurse Practitioners. 2019 Oct; 15(9): 622-6. doi: 10.1016/j.nurpra.2019.06.008. DOI: https://doi.org/10.1016/j.nurpra.2019.06.008

Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT. Evolution of NAFLD and its management. Nutrition in Clinical Practice. 2020 Feb; 35(1): 72-84. doi: 10.1002/ncp.10449. DOI: https://doi.org/10.1002/ncp.10449

Bonacini M, Kassamali F, Kari S, Barrera NL, Kohla M. Racial differences in prevalence and severity of non-alcoholic fatty liver disease. World Journal of Hepatology. 2021 Jul; 13(7): 763. doi: 10.4254/wjh.v13.i7.763. DOI: https://doi.org/10.4254/wjh.v13.i7.763

Lv Y, Zhang J, Yang T, Sun J, Hou J, Chen Z et al. Non-alcoholic fatty liver disease (NAFLD) is an independent risk factor for developing new-onset diabetes after acute pancreatitis: A multicenter retrospective cohort study in Chinese population. Frontiers in Endocrinology. 2022 May; 13: 903731. doi: 10.3389/fendo.2022.903731. DOI: https://doi.org/10.3389/fendo.2022.903731

Vaishya, R., Gupta, B. M., Kappi, M. M., Misra, A., Kuchay, M. S., & Vaish, A. (2023). Research on non-alcoholic fatty liver disease from Indian subcontinent: A bibliometric analysis of publications during 2001–2022. Journal of Clinical and Experimental Hepatology. DOI: https://doi.org/10.1016/j.jceh.2023.08.007

Wang, Z., Ye, M., Zhang, X. J., Zhang, P., Cai, J., Li, H., & She, Z. G. (2022). Impact of NAFLD and its pharmacotherapy on lipid profile and CVD. Atherosclerosis, 355, 30-44. DOI: https://doi.org/10.1016/j.atherosclerosis.2022.07.010

Shabalala SC, Dludla PV, Mabasa L, Kappo AP, Basson AK, Pheiffer C et al. The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. Biomedicine and Pharmacotherapy. 2020 Nov; 131: 110785. doi: 10.1016/j.biopha.2020.110785. DOI: https://doi.org/10.1016/j.biopha.2020.110785

Ojiako OA and Akubugwo EI. An introductory approach to practical biochemistry. CPL, Owerri. 1997.

Amzolini, A. M., Forţofoiu, M. C., Abu-Alhija, A. B., Vladu, I. M., Clenciu, D., Mitrea, A., ... & Micu, E. S. (2021). Triglyceride and glucose index: a useful tool for non-alcoholic liver disease assessed by liver biopsy in patients with metabolic syndrome?. Romanian Journal of Morphology and Embryology, 62(2), 475. DOI: https://doi.org/10.47162/RJME.62.2.13

Mavilia MG and Wu GY. Liver and serum adiponectin levels in non‐alcoholic fatty liver disease. Journal of Digestive Diseases. 2021 Apr; 22(4): 214-21. doi: 10.1111/1751-2980.12980. DOI: https://doi.org/10.1111/1751-2980.12980

Huh Y, Cho YJ, Nam GE. Recent epidemiology and risk factors of nonalcoholic fatty liver disease. Journal of Obesity & Metabolic Syndrome. 2022 Mar; 31(1): 17. doi: 10.7570/jomes22021. DOI: https://doi.org/10.7570/jomes22021

Murag S, Ahmed A, Kim D. Recent epidemiology of nonalcoholic fatty liver disease. Gut and liver. 2021 Mar; 15(2): 206. doi.org/10.5009/gnl20127. DOI: https://doi.org/10.5009/gnl20127

Kechagias S, Nasr P, Blomdahl J, Ekstedt M. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism. 2020 Oct 1;111:154183.

Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. The Lancet. 2021 Jun 5;397(10290):2212-24. DOI: https://doi.org/10.1016/S0140-6736(20)32511-3

Miura K, Arai N, Goka R, Morimoto N, Watanabe S, Isoda N et al. Oxidized High-Density Lipoprotein Shows a Stepwise Increase as Fibrosis Progresses in Patients with Nonalcoholic Fatty Liver Disease. Antioxidants. 2021 Feb; 10(2): 239. doi: 10.3390/antiox10020239. DOI: https://doi.org/10.3390/antiox10020239

Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, Han M. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduction and Targeted Therapy. 2022 Apr; 7(1): 131. doi: 10.1038/s41392-022-00955-7. DOI: https://doi.org/10.1038/s41392-022-00955-7

Yang S and Xu J. Elevated small dense low‐density lipoprotein cholesterol to high‐density lipoprotein cholesterol ratio is associated with an increased risk of metabolic dysfunction associated fatty liver disease in Chinese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation. 2024 May; 15(5): 634-42. doi: 10.1111/jdi.14148. DOI: https://doi.org/10.1111/jdi.14148

Hwang HW, Yu JH, Jin YJ, Suh YJ, Lee JW. Correlation between the small dense LDL level and nonalcoholic fatty liver disease: Possibility of a new biomarker. Medicine. 2020 Jul; 99(28): e21162. doi: 10.1097/MD.0000000000021162. DOI: https://doi.org/10.1097/MD.0000000000021162

Loaeza-Reyes KJ, Zenteno E, Moreno-Rodríguez A, Torres-Rosas R, Argueta-Figueroa L, Salinas-Marín R, Castillo-Real LM, Pina-Canseco S, Cervera YP. An overview of glycosylation and its impact on cardiovascular health and disease. Frontiers in molecular biosciences. 2021 Nov 16;8:751637. DOI: https://doi.org/10.3389/fmolb.2021.751637

Kechagias S, Nasr P, Blomdahl J, Ekstedt M. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism. 2020 Oct 1;111:154183. DOI: https://doi.org/10.1016/j.metabol.2020.154183

Zhang YN, Wang QQ, Chen YS, Shen C, Xu CF. Association between serum uric acid to HDL‐cholesterol ratio and nonalcoholic fatty liver disease in lean Chinese adults. International Journal of Endocrinology. 2020 Mar; 2020(1): 5953461. doi: 10.1155/2020/5953461. DOI: https://doi.org/10.1155/2020/5953461

Shahab O, Biswas R, Paik J, Bush H, Golabi P, Younossi ZM. Among patients with NAFLD, treatment of dyslipidemia does not reduce cardiovascular mortality. Hepatology Communications. 2018 Oct; 2(10): 1227-34. doi: 10.1002/hep4.1241. DOI: https://doi.org/10.1002/hep4.1241

Kawaguchi K, Sakai Y, Terashima T, Shimode T, Seki A, Orita N et al. Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease. Medicine. 2021 Aug; 100(31): e26835. doi: 10.1097/MD.0000000000026835. DOI: https://doi.org/10.1097/MD.0000000000026835

Tavaglione F, Jamialahmadi O, De Vincentis A, Qadri S, Mowlaei ME, Mancina RM, Ciociola E, Carotti S, Perrone G, Bruni V, Gallo IF. Development and validation of a score for fibrotic nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology. 2023 Jun 1;21(6):1523-32. DOI: https://doi.org/10.1016/j.cgh.2022.03.044

Amernia B, Moosavy SH, Banookh F, Zoghi G. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran. BMC gastroenterology. 2021 Dec;21:1-7. DOI: https://doi.org/10.1186/s12876-021-02038-3